Clinical Trial Update: Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase II trial investigating Almonertinib in combination with Lastet for EGFR-positive non-small cell lung cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)
• Lastet

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Lung Cancer Non-small Cell Stage IV | Phase 2 | Status: NOT_YET_RECRUITING